ARWR News and Press, Arrowhead Pharmaceuticals Inc. From 05/11/22

Image source: The Motley Fool. Arrowhead Pharmaceuticals (NASDAQ: ARWR) Q2 2022 Earnings Call May 10, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Arrowhead Pharmaceuticals (ARWR) Q2 2022 Earnings Call Transcript...

Arrowhead Pharmaceuticals, Inc. (ARWR) Q2 2022 Earnings Conference Call May 10, 2022, 04:30 PM ET Company Participants Vince Anzalone - VP, IR Christopher Anzalone - President and CEO Javier San Martin - Chief Medical Officer Ken Myszkowski - CFO James Hamilton - SVP, Discovery and Translatio...

Arrowhead Pharmaceuticals press release (NASDAQ:ARWR): Q2 GAAP EPS of $0.41 beats by $0.12. Revenue of $151.8M (+362.7% Y/Y) beats by $29.65M. For further details see: Arrowhead Pharmaceuticals GAAP EPS of $0.41 beats by $0.12, revenue of $151.8M beats by $29.65M

- Conference Call and Webcast Today, May 10, 2022 at 4:30 p.m. ET Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal second quarter ended March 31, 2022. The company is hosting a conference call today, May 10, 2022, at 4:30 p.m. ET to...

Arrowhead Pharmaceuticals (NASDAQ:ARWR) is scheduled to announce FQ2 earnings results on Tuesday, May 10th, after market close. The consensus EPS Estimate is $0.18 (+169.2% Y/Y) and the consensus Revenue Estimate is $122.15M (+272.3% Y/Y). Over the last 1 year, ARWR has beaten EPS estimates 2...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today held a groundbreaking ceremony in Verona, WI, on the site which will house a new approximately 160,000 square foot drug manufacturing facility and an approximately 125,000 square foot laboratory and office facility to support process ...

My portfolio, built specifically for my retirement ~20+ years from now, is finally beating my S&P 500 benchmark for the year. Making monthly contributions, even though they seem small at the time, makes all the difference in the world over time in helping create a valuable retirem...

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that the board of directors appointed veteran pharmaceutical industry executive Victoria Vakiener, as an independent director of the company, with a term beginning effective May 2, 2022. Douglass Given, M.D., Ph.D., Chair...

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: TIDES USA 2022: Oligonucleotide and Peptide Therapeutics – May 9-12, 2022 Title: Arrowhead’s Approach to Oligonucleotide Scale-...

The following slide deck was published by Arrowhead Pharmaceuticals, Inc. in conjunction with this event. For further details see: Oligonucleotide-Based Therapeutics Conference